Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH.

Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH.

Osteocytes remodel the perilacunar matrix and canaliculi. X-linked hypophosphatemia (XLH) is characterized by elevated serum levels of fibroblast growth factor 23 (FGF23), leading to decreased 1,25 dihydroxyvitamin D3 (1,25D) production and hypophosphatemia. Bones from mice with XLH (Hyp) have enlar...

Full description

Bibliographic Details
Main Authors:	Ye Yuan, Supriya Jagga, Janaina S Martins, Rakshya Rana, Paola Divieti Pajevic, Eva S Liu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2021-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0252348

Similar Items

Impaired 1,25-dihydroxyvitamin D3 action underlies enthesopathy development in the Hyp mouse model of X-linked hypophosphatemia
by: Rakshya Rana, et al.
Published: (2023-09-01)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
by: Kelsey A. Carpenter, et al.
Published: (2023-10-01)

The small world of osteocytes: connectomics of the lacuno-canalicular network in bone
by: Philip Kollmannsberger, et al.
Published: (2017-01-01)

Third harmonic generation imaging and analysis of the effect of low gravity on the lacuno-canalicular network of mouse bone.
by: Rachel Genthial, et al.
Published: (2019-01-01)

Image analysis pipeline for segmentation of a biological porosity network, the lacuno-canalicular system in stingray tesserae
by: Merlind Schotte, et al.
Published: (2020-01-01)

Detailing the influence of PEO-coated biodegradable Mg-based implants on the lacuno-canalicular network in sheep bone: A pilot study
by: Jonathan Espiritu, et al.
Published: (2023-08-01)

Ptychographic X-ray CT characterization of the osteocyte lacuno-canalicular network in a male rat's glucocorticoid induced osteoporosis model
by: Antonia Ciani, et al.
Published: (2018-12-01)

X-linked hypophosphatemia (XLH): Mutations compromising PHEX structure reflect a severe phenotype
by: Whyte, M, et al.
Published: (1999)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
by: Rafi Brener, et al.
Published: (2022-08-01)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
by: Aaron Schindeler, et al.
Published: (2020-05-01)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
by: Avivit Brener, et al.
Published: (2021-03-01)

Insights into the Molecular and Hormonal Regulation of Complications of X-Linked Hypophosphatemia
by: Supriya Jagga, et al.
Published: (2023-03-01)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
by: Gema Ariceta, et al.
Published: (2023-09-01)

Kbus/Idr, a mutant mouse strain with skeletal abnormalities and hypophosphatemia: Identification as an allele of 'Hyp'
by: Kimura Atsushi, et al.
Published: (2011-08-01)

Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts
by: Maria Helena Vaisbich, et al.
Published: (2024-02-01)

Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study
by: Gabriel T. Mindler, et al.
Published: (2022-03-01)

A PAI‐1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D‐resistant rickets model mouse
by: Cheng Qian, et al.
Published: (2024-02-01)

Biomechanical Impact of Phosphate Wasting on Articular Cartilage Using the Murine Hyp Model of X‐linked hypophosphatemia
by: Carolyn M Macica, et al.
Published: (2023-10-01)

THE PRODUCTION OF 1,25-DIHYDROXYVITAMIN-D IN PRIMARY HYPERPARATHYROIDISM
by: Thakker, R, et al.
Published: (1986)

P251: XLH molecular diagnoses and the PHEX gene variant landscape: Sponsored hypophosphatemia gene panel testing findings from 2019 vs 2022
by: Nicole Miller, et al.
Published: (2023-01-01)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
by: Lothar Seefried, et al.
Published: (2023-10-01)

Serum 1,25-dihydroxyvitamin D: an outcome prognosticator in human sepsis.
by: H Bryant Nguyen, et al.
Published: (2013-01-01)

Focus on 1,25-Dihydroxyvitamin D3 in the Peripheral Nervous System
by: Pierre Antoine Faye, et al.
Published: (2019-04-01)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
by: Yuichi Takashi, et al.
Published: (2022-12-01)

The recommended starting dose of 0.4mg/kg burosumab is insufficient for most children with X-linked hypophosphatemia (XLH) - Results from the first treated patients in Sweden
by: Sigrun Hallgrimsdottir, et al.
Published: (2020-10-01)

Circulating concentrations of 1,25-dihydroxyvitamin D3 in patients with primary hyperparathyroidism.
by: Thakker, R, et al.
Published: (1986)

Modulation of 1,25-dihydroxyvitamin D3 receptor by phospholipids and fatty acids.
by: T C Chen, et al.
Published: (1984-12-01)

Outcomes of canalicular trephination versus canaliculodacryocystorhinostomy in common canalicular blocks
by: Tejaswini Vukkadala, et al.
Published: (2022-01-01)

Glucocorticoids cause mandibular bone fragility and suppress osteocyte perilacunar-canalicular remodeling
by: A. Sean Alemi, et al.
Published: (2018-12-01)

Primary human osteoblasts in response to 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3.
by: Karen van der Meijden, et al.
Published: (2014-01-01)

1,25-Dihydroxyvitamin D3 regulates furin-mediated FGF23 cleavage
by: Han Xie, et al.
Published: (2023-09-01)

Immunohistochemical Analysis of 1.25-dihydroxyvitamin D3 Receptor Expression in Endometrial Cancer
by: Nesibe Kahraman Çetin, et al.
Published: (2021-06-01)

Effects of 1,25-dihydroxyvitamin D3 on pathological changes in rats with diabetic cardiomyopathy
by: Xiaoyun Zeng, et al.
Published: (2017-06-01)

1,25-Dihydroxyvitamin D promotes calcium influx in human skeletal muscle myotubes
by: Chun Zhang, et al.
Published: (2017-09-01)

Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial
by: Peter Kamenický, et al.
Published: (2020-10-01)

Adenoma canalicular traqueal
by: Carrasco Carrasco CM, et al.
Published: (2020-11-01)

Tratamiento Quirúrgico de las interrupciones canaliculares Surgical treatment of canalicular disruptions
by: Nereyda Martínez Suárez, et al.
Published: (1999-06-01)

Clinical research on the treatment of dacryocystitis combined with canalicular obstruction by dacryocystorhinostomy with canalicular intubation
by: Xin-Jun Xue, et al.
Published: (2014-07-01)

The ankle in XLH: Reduced motion, power and quality of life
by: Celine Akta, et al.
Published: (2023-03-01)

1,25-Dihydroxyvitamin-D3 Induces Avian β-Defensin Gene Expression in Chickens.
by: Long Zhang, et al.
Published: (2016-01-01)